By Laura Serrano / November 16, 2021
At Nuwellis, innovation and collaboration is one of our key strategic imperatives. The healthcare and medical device industries are ever-evolving, and we’re constantly striving to improve both patient and practitioner experiences. We were honored to receive the R&D 100 Award in the Analytical/Test category for the Aquadex SmartFlow system in October – an award that recognizes pioneers in research and development and revolutionary ideas in science and technology.
“As a small medical device company, Nuwellis is constantly looking to expand our product portfolio and for new ways the Aquadex system can be used to improve lives,” said Vitaliy Epshteyn, Senior Vice President – Operations & Engineering. “It’s crucial we avoid becoming stagnant, and innovation is the only way for us to meet our mission of transforming the lives of patients suffering from fluid overload.”
The Aquadex system simply, safely, and predictably removes excess fluid (primarily salt and water) from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis is focused on bringing this innovative treatment to three primary areas: heart failure, critical care, and pediatrics.
“Heart failure and critical care make up a large market opportunity for Nuwellis in the adult patient population,” said Epshteyn. “Pediatrics is a smaller overall market, and one that larger companies don’t necessarily want to pursue. We want to help our most vulnerable patients and play a leading role in that market. We are actively innovating to address current and future needs of the pediatric patients.”
Critically-ill children and infants with kidney failure – or who are dependent on artificial kidney support – currently do not have enough therapeutic options. In 2020, Nuwellis took a step towards better supporting this population with FDA approval of the Aquadex system to treat pediatric patients weighing 20 kg (44 lbs) or more. And while an important step, it was not enough for the very smallest patients.
In August 2021, Nuwellis announced plans to address this unmet need head-on, with the development of a fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for some of the smallest babies and children. The new device will build on Nuwellis’s expertise in fluid balance therapies and improve access to lifesaving care.
“Anything we can do to further integrate new technologies into the Aquadex system, like diagnostics and automation, will help us pioneer new therapies and ultimately reach our goal of enhancing experiences for patients and their healthcare providers, and reduce the overall healthcare costs” Epshteyn said.
“Our partners believe in our work and the industry is taking note.
It’s an honor to be recognized in the R&D 100 Awards. The future
of Nuwellis looks bright.”
Click here for more information about
the latest innovation in ultrafiltration.